Weight-Loss “Anti-Obesity” Medications Remain Inaccessible to Demographics Who Truly Need Them
Harvard Undergraduate Health Policy Review · 2024 · 24 (1)
DOI: 10.56927/897463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Harvard Undergraduate Health Policy Review, 2024. Verfasst von Fhasal Alam.
Abstract (Originalsprache)
The conversation surrounding prescription weight-loss medications, or “anti-obesity” drugs, has skyrocketed amidst new developments. Wegovy and Ozempic, two weight-loss drugs that recently entered the market, have given patients in the United States the tools to control their weight—perhaps without
Zitieren
APA
Alam, F. (2024). Weight-Loss “Anti-Obesity” Medications Remain Inaccessible to Demographics Who Truly Need Them. Harvard Undergraduate Health Policy Review, 24(1). https://doi.org/10.56927/897463
Vancouver
Alam F. Weight-Loss “Anti-Obesity” Medications Remain Inaccessible to Demographics Who Truly Need Them. Harvard Undergraduate Health Policy Review. 2024;24(1). doi:10.56927/897463
BibTeX
@article{Alam2024,
author = {Alam, Fhasal},
title = {Weight-Loss “Anti-Obesity” Medications Remain Inaccessible to Demographics Who Truly Need Them},
journal = {Harvard Undergraduate Health Policy Review},
year = {2024},
volume = {24},
number = {1},
doi = {10.56927/897463}
}
EUVIMED